Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Lifted by Silvant Capital Management LLC

Silvant Capital Management LLC raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,009 shares of the biotechnology company’s stock after purchasing an additional 2,950 shares during the period. Silvant Capital Management LLC’s holdings in Sarepta Therapeutics were worth $3,498,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Capital International Investors raised its holdings in shares of Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after purchasing an additional 76,032 shares in the last quarter. Farallon Capital Management LLC raised its holdings in Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after buying an additional 37,940 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Sarepta Therapeutics by 26.3% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock worth $75,040,000 after purchasing an additional 120,535 shares during the last quarter. Finally, abrdn plc boosted its position in Sarepta Therapeutics by 30.7% during the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock worth $53,935,000 after purchasing an additional 101,253 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $123.29 on Friday. The firm has a market capitalization of $11.76 billion, a P/E ratio of 273.98 and a beta of 0.82. The stock has a fifty day moving average price of $127.42 and a two-hundred day moving average price of $132.56. Sarepta Therapeutics, Inc. has a 52-week low of $75.69 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.27) EPS. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on SRPT. Cantor Fitzgerald reissued a “neutral” rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a research report on Friday, September 20th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Evercore ISI raised Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and lowered their price target for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. Barclays cut their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $182.95.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.